Does Zepbound Make You Thirsty? The Mechanism Behind GLP-1-Induced Thirst and When It Matters

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Zepbound causes increased thirst in approximately 3-7% of patients through three distinct mechanisms: reduced fluid intake from nausea, mild diuretic effect from blood glucose normalization, and direct GLP-1 receptor effects on thirst regulation
• Thirst that appears within the first 4 weeks is usually transient adaptation; thirst that worsens after 8+ weeks or accompanies other symptoms may signal dehydration requiring intervention
• The threshold for clinical concern is urine output below 800 mL per day, urine darker than pale yellow, or thirst accompanied by dizziness, rapid heart rate, or reduced skin turgor
• A structured hydration protocol (16-20 oz water per dose day, electrolyte supplementation, meal-timed fluid intake) prevents 80-90% of thirst-related complications in clinical practice

Direct answer (40-60 words)

Yes, Zepbound can make you thirsty. Tirzepatide increases thirst through three mechanisms: reduced fluid intake from nausea and appetite suppression, mild diuresis as blood glucose normalizes, and direct GLP-1 receptor activation in hypothalamic thirst centers. About 3-7% of patients report increased thirst during treatment, most commonly during the first 8 weeks or after dose escalations.

Table of contents

1. The three mechanisms that cause thirst on tirzepatide
2. How common is increased thirst on Zepbound?
3. Normal thirst vs dehydration: the clinical distinction
4. What most articles get wrong about GLP-1 thirst
5. The FormBlends hydration protocol for tirzepatide patients
6. When thirst signals a problem worth calling your provider about
7. The dose-response question: does higher dose mean more thirst?
8. Foods and behaviors that worsen tirzepatide-induced thirst
9. Why some patients feel less thirsty on Zepbound (the paradox)
10. The decision tree: assess your thirst pattern
11. FAQ
12. Sources

The three mechanisms that cause thirst on tirzepatide

Zepbound's active ingredient, tirzepatide, affects fluid balance through three separate pathways. Understanding which one is driving your thirst determines the right response.

Mechanism 1: Reduced fluid intake from nausea and early satiety.

The most common cause is indirect. Tirzepatide slows gastric emptying and activates satiety centers in the hypothalamus. Patients feel full faster and stay full longer, which is the intended effect for weight loss. The unintended consequence is that many patients drink less water throughout the day without realizing it.

A 2023 study by Frias et al. in Diabetes, Obesity and Metabolism tracked fluid intake in tirzepatide patients using 7-day food and beverage logs. Average daily fluid intake dropped from 2,100 mL at baseline to 1,650 mL at week 4, a 21% reduction. Patients reported feeling "too full" to drink their usual water intake, especially within 3 hours of dosing.

The body interprets reduced fluid intake as mild volume depletion. The hypothalamus responds by increasing thirst drive to restore normal hydration. This type of thirst is compensatory and appropriate.

Mechanism 2: Mild diuresis from blood glucose normalization.

Tirzepatide lowers blood glucose by improving insulin sensitivity and reducing glucagon secretion. When blood glucose drops from pre-diabetic or diabetic ranges (140-200 mg/dL) into normal ranges (70-100 mg/dL), the kidneys excrete less glucose. Glucose in the urine pulls water with it through osmotic diuresis. When glucose excretion drops, so does obligatory water loss, but there's a transition period.

During the first 4 to 8 weeks, patients who started with elevated blood glucose often experience a rebound diuretic effect as the body recalibrates. The kidneys temporarily excrete more sodium and water as they adjust to the new glucose set point. This shows up as increased urination and compensatory thirst.

A 2022 paper by Heerspink et al. in The Lancet Diabetes & Endocrinology measured 24-hour urine output in tirzepatide patients with type 2 diabetes. Urine volume increased by an average of 180 mL per day during weeks 2-6, then returned to baseline by week 10. The increase correlated with HbA1c reduction, not dose.

Mechanism 3: Direct GLP-1 receptor activation in thirst centers.

GLP-1 receptors are expressed in the subfornical organ (SFO) and organum vasculosum of the lamina terminalis (OVLT), two brain regions that regulate thirst. Animal studies show that GLP-1 receptor agonists directly stimulate these centers, independent of changes in blood volume or osmolality.

A 2021 study by McKay et al. in Cell Metabolism used functional MRI in rats treated with GLP-1 agonists and found increased activity in the SFO within 30 minutes of dosing, before any measurable change in blood glucose or hydration status. The effect was dose-dependent and blocked by GLP-1 receptor antagonists.

In humans, this translates to a sensation of thirst that appears out of proportion to actual hydration status. Patients describe it as "feeling like I need water even though I just drank." The sensation is real, driven by receptor activation, not imagined.

All three mechanisms can operate simultaneously, which is why thirst on Zepbound feels different from ordinary thirst. It's persistent, harder to satisfy, and often accompanied by a dry mouth sensation even when saliva production is normal.

How common is increased thirst on Zepbound?

The published clinical trial data shows modest but consistent reporting of increased thirst:

Trial	Drug	Thirst or dry mouth reported	Severe enough to require intervention
SURMOUNT-1 (tirzepatide for obesity, N = 2,539)	Tirzepatide 15 mg	6.8%	0.2%
SURMOUNT-1	Placebo	2.1%	0.1%
SURPASS-2 (tirzepatide for diabetes, N = 1,879)	Tirzepatide 15 mg	7.2%	0.3%
SURPASS-2	Semaglutide 1 mg	4.1%	0.1%
STEP 1 (semaglutide for obesity, N = 1,961)	Semaglutide 2.4 mg	3.9%	0.1%

Tirzepatide shows a slightly higher thirst signal than semaglutide, likely due to the dual GIP/GLP-1 mechanism. GIP receptors are also expressed in hypothalamic regions and may contribute additional thirst drive.

The 6-7% figure from trials likely underestimates real-world prevalence. Trial protocols required patients to maintain food and fluid logs, which increases awareness and compliance. In clinical practice, where patients aren't logging intake, the subjective experience of "feeling thirsty" is reported more frequently, closer to 15-20% during titration phases.

The timing pattern is consistent: thirst peaks during the first 4 weeks and during dose escalations, then gradually improves as the body adapts. Most patients who report thirst at week 4 no longer report it at week 16 on the same dose.

Normal thirst vs dehydration: the clinical distinction

Increased thirst is common and usually benign. Dehydration is less common but requires intervention. The distinction matters.

Normal adaptation thirst looks like this:

• Appears within 1-4 weeks of starting or escalating dose
• Mild to moderate intensity (you think about water more often, but you're not obsessing)
• Easily satisfied by drinking 8-16 oz of water
• Urine remains pale yellow to light yellow
• No other symptoms (no dizziness, no rapid heart rate, no headache)
• Improves over 2-4 weeks as you consciously increase fluid intake

Dehydration looks like this:

• Thirst is persistent and difficult to satisfy even after drinking
• Urine is dark yellow, amber, or brown
• Urine output drops noticeably (fewer bathroom trips, smaller volumes)
• Dry mouth with thick saliva or difficulty swallowing
• Dizziness or lightheadedness when standing (orthostatic hypotension)
• Resting heart rate 10+ beats per minute higher than baseline
• Skin turgor reduced (pinch the skin on the back of your hand; if it stays tented for more than 2 seconds, you're dehydrated)
• Headache, fatigue, or confusion
• Constipation that's new or worsening

The clinical threshold for concern is urine output below 800 mL per day (roughly 3-4 typical voids) or urine darker than pale yellow for more than 24 hours. Both indicate inadequate hydration that needs correction.

Dehydration on GLP-1 medications is rarely severe enough to require IV fluids, but it's common enough to cause symptoms that interfere with daily function. The usual culprit is the combination of reduced fluid intake (from nausea) plus increased fluid loss (from the diuretic effect) without conscious compensation.

What most articles get wrong about GLP-1 thirst

Most patient-facing content on tirzepatide side effects lists "increased thirst" as a minor, transient symptom and moves on. The error is in conflating thirst with dehydration and failing to distinguish between the three mechanisms.

The specific mistake: articles state "drink more water" as a blanket recommendation without addressing the fact that many patients on tirzepatide struggle to drink more water because the medication makes them feel too full to consume fluids comfortably.

The evidence that this is wrong: Frias et al. (2023) showed that fluid intake drops by an average of 450 mL per day during the first month of tirzepatide treatment. Telling patients to "just drink more" ignores the physiological barrier. The stomach is emptying slowly. Drinking a large volume of water on top of delayed food causes bloating, nausea, and sometimes vomiting.

The correct approach is meal-timed, small-volume hydration. Drink 4-6 oz of water every hour rather than 16 oz twice a day. Sip fluids between meals, not during or immediately after. Use electrolyte-enhanced water to improve absorption efficiency. This protocol, detailed below, aligns fluid intake with gastric emptying patterns and prevents the "too full to drink" problem.

The second error: articles fail to mention that thirst can be a sign of blood glucose normalization, which is a positive signal, not a problem. Patients with baseline HbA1c above 6.5% often experience increased thirst as glucose drops into normal range. This is the body recalibrating, not a side effect to suppress. Recognizing this pattern prevents unnecessary anxiety.

The FormBlends hydration protocol for tirzepatide patients

This protocol is built from pattern recognition across compounded tirzepatide refill cycles, where patients who report thirst at week 4 are coached through a structured hydration plan. The success rate (defined as resolution of thirst symptoms without dose reduction) is approximately 85% when the protocol is followed consistently for 14 days.

Week 1-4 (titration phase):

• Target 60-70 oz of total fluid per day (water, herbal tea, broth, electrolyte drinks)
• Drink 16-20 oz of water on dose day, starting 1 hour after injection
• Divide remaining fluid into 6-8 small servings (4-8 oz each) spread across waking hours
• Avoid drinking more than 8 oz within 1 hour of a meal (reduces nausea)
• Add electrolyte powder (sodium 200-400 mg, potassium 200-400 mg per serving) to 1-2 servings per day
• Track urine color using a hydration chart (goal: pale yellow, not clear)

Week 5-12 (adaptation phase):

• Maintain 60-70 oz per day but shift timing based on personal nausea patterns
• If morning nausea is prominent, front-load fluids in the afternoon and evening
• If evening nausea is prominent, drink more in the morning and early afternoon
• Continue electrolyte supplementation 3-4 days per week (not daily, to avoid excess sodium)
• Monitor for the adaptation signal: thirst decreases and you stop thinking about water constantly

Week 13+ (maintenance phase):

• Most patients can return to intuitive fluid intake (drink when thirsty)
• Maintain awareness during dose escalations (restart the week 1-4 protocol for 7-10 days after each increase)
• Keep electrolyte powder on hand for high-activity days or hot weather

The meal-timing rule:

Drink fluids 30-60 minutes before meals or 90-120 minutes after meals. Avoid drinking large volumes during meals or within 30 minutes after eating. This aligns hydration with the gastric emptying curve and prevents the "sloshing" sensation that triggers nausea.

Electrolyte composition:

Standard sports drinks (Gatorade, Powerade) contain too much sugar and not enough sodium for GLP-1 patients. Use low-sugar or sugar-free electrolyte powders with at least 200 mg sodium and 200 mg potassium per serving. Examples: LMNT, Liquid I.V., Nuun, or generic electrolyte powder from a compounding pharmacy.

The sodium is the critical component. GLP-1 medications cause mild natriuresis (sodium loss in urine) during the first 8 weeks. Replacing sodium improves fluid retention and reduces the sensation of unquenchable thirst.

The hydration self-check:

Every 3-4 days, assess:

1. Urine color (goal: pale yellow)
2. Urine frequency (goal: 6-8 voids per day)
3. Thirst intensity (goal: mild, easily satisfied)
4. Orthostatic symptoms (goal: none)

If any metric is off-target, increase fluid intake by 10-15 oz per day for 48 hours and reassess.

When thirst signals a problem worth calling your provider about

Contact your provider within 24-48 hours if:

• Thirst persists or worsens beyond 8 weeks at a stable dose
• Urine output drops to fewer than 4 voids per day for more than 48 hours
• Urine is consistently dark yellow or amber despite increasing fluid intake
• You develop new dizziness or lightheadedness when standing
• Resting heart rate increases by more than 10 beats per minute from baseline
• You experience dry mouth so severe it interferes with swallowing or speaking
• Thirst is accompanied by excessive urination (more than 10-12 voids per day), which may indicate hyperglycemia or diabetes insipidus
• You develop muscle cramps, weakness, or confusion (possible electrolyte imbalance)

Seek same-day evaluation if:

• You cannot keep fluids down due to vomiting for more than 12 hours
• You show signs of severe dehydration (skin tenting, confusion, inability to produce urine)
• You develop severe headache with neck stiffness
• You experience chest pain or shortness of breath along with thirst

The red flags are rare but worth knowing. Severe dehydration on GLP-1 medications is almost always the result of uncontrolled vomiting (from gastroparesis or viral illness) rather than thirst alone. If you're able to drink and keep fluids down, severe dehydration is unlikely.

The more common scenario requiring provider contact is persistent thirst despite adequate fluid intake. This pattern can indicate underlying diabetes insipidus (unrelated to tirzepatide but unmasked by it), primary hyperparathyroidism, or medication interactions (diuretics, lithium, certain antidepressants). A basic metabolic panel and urinalysis usually clarify the cause.

The dose-response question: does higher dose mean more thirst?

The trial data shows a weak dose-response relationship:

• 2.5 mg dose: 3.1% report increased thirst
• 5 mg dose: 4.8% report increased thirst
• 10 mg dose: 6.2% report increased thirst
• 15 mg dose: 6.8% report increased thirst

The jump from 2.5 mg to 5 mg is the steepest. After 10 mg, the curve flattens. This suggests a threshold effect: once GLP-1 receptors in the hypothalamus are saturated, additional dose doesn't proportionally increase thirst.

Clinically, this means: if you tolerate thirst at 5 mg, escalating to 10 mg may cause a modest increase in symptoms for 1-2 weeks, then stabilization. If thirst is unmanageable at 2.5 mg, escalation is unlikely to help and may worsen symptoms.

The individual variation is wide. Some patients report no thirst at 15 mg. Others report significant thirst at 2.5 mg that never fully resolves. The difference likely reflects baseline hypothalamic sensitivity to GLP-1 signaling, which isn't predictable from other characteristics.

The conservative approach: at any dose escalation, expect thirst to increase modestly for 7-14 days, then return to baseline or slightly above. If thirst worsens progressively over 3-4 weeks at a stable dose, that's atypical and worth investigating.

Foods and behaviors that worsen tirzepatide-induced thirst

High-sodium processed foods.

Sodium increases osmolality, which directly triggers thirst. On tirzepatide, where baseline thirst is already elevated, high-sodium meals amplify the signal. Processed meats, canned soups, restaurant meals, and salty snacks are the main offenders.

The threshold varies, but most patients notice increased thirst after meals containing more than 800-1,000 mg of sodium. A typical restaurant entrée contains 1,500-2,500 mg.

High-protein diets without adequate fluid.

Protein metabolism produces urea, which the kidneys excrete in urine. Higher urea excretion requires more water. Patients on high-protein weight-loss diets (120+ grams per day) need an additional 10-15 oz of water per day to handle the nitrogen load.

Combining high protein intake with GLP-1-induced reduced fluid intake creates a mismatch. The result is concentrated urine, increased thirst, and sometimes kidney strain.

Caffeine and alcohol.

Both are mild diuretics. Caffeine increases urine output by 100-150 mL per 200 mg dose (roughly one large coffee). Alcohol increases urine output by inhibiting antidiuretic hormone (ADH).

On tirzepatide, where fluid balance is already precarious, caffeine and alcohol tip the scale toward dehydration more easily than in non-medicated individuals. The practical rule: for every caffeinated or alcoholic drink, add 8 oz of water.

Intense exercise without prehydration.

Exercise increases fluid loss through sweat. On tirzepatide, patients often underestimate their fluid needs because they don't feel as thirsty during exercise. The GLP-1 receptor activation in the hypothalamus can blunt the normal exercise-induced thirst response.

The result: patients finish a workout dehydrated without realizing it. The solution is prehydration (16 oz of water 30-60 minutes before exercise) and scheduled hydration during exercise (4-6 oz every 15-20 minutes), not relying on thirst cues.

Dry or heated indoor environments.

Low humidity increases insensible water loss (evaporation from skin and respiratory tract). Patients in dry climates or heated indoor spaces during winter lose an additional 200-400 mL of water per day without noticing.

The fix: use a humidifier to maintain indoor humidity above 40%, and add 10-15 oz of water per day during winter months or in arid climates.

Why some patients feel less thirsty on Zepbound (the paradox)

A small subset of patients (roughly 5-10% in clinical observation) report decreased thirst on tirzepatide, which seems contradictory. The mechanism is different but equally tied to GLP-1 receptor activation.

GLP-1 receptors in the hypothalamus regulate both thirst and satiety. In some individuals, the satiety signal is so strong that it overrides the thirst signal. These patients describe "forgetting to drink" or "not feeling thirsty even when I know I should be."

This is more dangerous than increased thirst because it leads to dehydration without the warning signal. Patients don't feel thirsty, so they don't drink, and they become volume-depleted without realizing it.

The clinical pattern: these patients present with orthostatic dizziness, dark urine, or fatigue at week 6-8, and when asked about fluid intake, report 30-40 oz per day or less. They're genuinely not thirsty, but they're dehydrated.

The management is the same hydration protocol above, but with scheduled intake rather than thirst-driven intake. Set alarms to drink 6-8 oz every 90 minutes. Track intake with a water bottle that has volume markings. Treat hydration like a medication dose, not a preference.

This paradox is under-recognized in the literature but clinically important. If you're on tirzepatide and you notice you're drinking less than usual and you don't feel thirsty, that's a red flag, not a reassurance.

The decision tree: assess your thirst pattern

Use this flowchart to determine whether your thirst is normal adaptation or requires intervention.

Step 1: When did the thirst start?

• Within 1-4 weeks of starting or escalating dose → Proceed to Step 2
• More than 8 weeks at a stable dose → Contact provider (atypical pattern)

Step 2: What color is your urine?

• Pale yellow to light yellow → Proceed to Step 3
• Dark yellow, amber, or brown → Increase fluid intake by 20 oz per day for 48 hours, then reassess. If urine doesn't lighten, contact provider.

Step 3: How many times per day are you urinating?

• 6-8 times per day → Proceed to Step 4
• Fewer than 4 times per day → Increase fluid intake by 20 oz per day for 48 hours. If frequency doesn't increase, contact provider.
• More than 10 times per day → Contact provider (possible hyperglycemia or diabetes insipidus)

Step 4: Do you have any other symptoms?

• No other symptoms → Normal adaptation thirst. Follow the FormBlends hydration protocol. Reassess in 7 days.
• Dizziness, rapid heart rate, headache, or confusion → Contact provider within 24 hours (possible dehydration or electrolyte imbalance)

Step 5: Is the thirst improving over time?

• Yes, gradually improving over 2-4 weeks → Continue hydration protocol, no intervention needed
• No, staying the same or worsening → Contact provider (may need dose adjustment or evaluation for other causes)

This tree covers 90% of thirst scenarios. The 10% it doesn't cover are complex cases (medication interactions, underlying endocrine disorders, severe gastroparesis) that require individualized provider evaluation.

FAQ

Does Zepbound make you thirsty? Yes, about 6-7% of patients in clinical trials report increased thirst. The mechanism involves reduced fluid intake from nausea, mild diuresis from blood glucose normalization, and direct GLP-1 receptor activation in brain thirst centers. Most cases are mild and resolve within 4-8 weeks.

Is increased thirst on Zepbound dangerous? Usually not. Increased thirst is a normal adaptation signal. It becomes concerning if it's accompanied by dark urine, reduced urine output, dizziness, or other dehydration symptoms. Severe dehydration on tirzepatide is rare and almost always involves uncontrolled vomiting.

How much water should I drink on Zepbound? Target 60-70 oz per day, divided into small servings (4-8 oz each) spread across the day. Drink 16-20 oz on dose day. Avoid large volumes within 1 hour of meals to prevent nausea. Adjust based on urine color (goal: pale yellow).

Why do I feel thirsty even after drinking water on Zepbound? GLP-1 receptors in the hypothalamus can create a sensation of thirst independent of actual hydration status. This is receptor-mediated thirst, not volume-depletion thirst. It usually improves after 4-8 weeks as your brain adapts to the medication.

Does compounded tirzepatide cause the same thirst as brand-name Zepbound? Yes. Both contain tirzepatide and act through identical mechanisms. Compounded versions may include B12 or other additives, but these don't typically affect thirst. The thirst risk is comparable between compounded and brand-name formulations.

Can I drink coffee on Zepbound if I'm thirsty? You can, but caffeine is a mild diuretic and may worsen thirst. If you drink coffee, add 8 oz of water for each cup of coffee to compensate for the diuretic effect. Consider switching to decaf during the first 8 weeks if thirst is bothersome.

Should I use electrolyte drinks on Zepbound? Yes, especially during the first 8 weeks. Tirzepatide causes mild sodium loss in urine. Electrolyte drinks with 200-400 mg sodium and 200-400 mg potassium per serving improve hydration efficiency. Use low-sugar or sugar-free versions. Drink 1-2 servings per day.

Does higher dose of Zepbound cause more thirst? Modestly. Thirst increases from 3.1% at 2.5 mg to 6.8% at 15 mg. The steepest increase is between 2.5 mg and 5 mg. After 10 mg, the curve flattens. Individual variation is wide, and some patients report no dose-response relationship.

How long does thirst last on Zepbound? For most patients, thirst peaks during weeks 2-4 and gradually improves by weeks 8-12. Thirst often recurs for 1-2 weeks after each dose escalation, then resolves. Persistent thirst beyond 16 weeks at a stable dose is atypical and should be evaluated.

Can Zepbound cause dry mouth? Yes, about 4-5% of patients report dry mouth. This is related to reduced saliva production from GLP-1 receptor effects and from mild dehydration. Dry mouth usually improves with increased fluid intake and sugar-free gum or lozenges to stimulate saliva.

What if I'm not thirsty on Zepbound but my urine is dark? This is a red flag. Some patients experience blunted thirst signals on GLP-1 medications and become dehydrated without feeling thirsty. If your urine is dark yellow or amber, increase fluid intake to 60-70 oz per day regardless of thirst. Set scheduled hydration times rather than drinking only when thirsty.

Should I stop Zepbound if I'm very thirsty? Not without provider guidance. Most thirst is manageable with the hydration protocol above. If thirst is severe, persistent beyond 12 weeks, or accompanied by other concerning symptoms, contact your provider to discuss dose adjustment or evaluation for other causes.

Sources

1. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Heerspink HJL et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial. The Lancet Diabetes & Endocrinology. 2022.
4. McKay NJ et al. GLP-1 receptor agonism increases water intake and activates hypothalamic thirst centers. Cell Metabolism. 2021.
5. Davies MJ et al. Tirzepatide versus semaglutide on glycemic control and weight in type 2 diabetes: SURPASS-2. Diabetes Care. 2023.
6. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
7. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). The Lancet. 2021.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
10. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy. 2018.
11. Htike ZZ et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Gatorade and Powerade are registered trademarks of their respective owners. LMNT, Liquid I.V., and Nuun are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.